Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 24, 2017
What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?
BRISTOL MYERS SQUIBB has seventy-eight approved drugs.| Patents: | 18 |
| Tradenames: | 66 |
| Ingredients: | 58 |
| NDAs: | 78 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SUSTIVA | efavirenz | TABLET;ORAL | 021360-002 | Feb 1, 2002 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Bristol Myers Squibb | MEGACE | megestrol acetate | TABLET;ORAL | 016979-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Bristol Myers Squibb | PENICILLIN G SODIUM | penicillin g sodium | INJECTABLE;INJECTION | 061935-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-003 | Jun 28, 2006 | AB | RX | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Bristol Myers Squibb | PRAVACHOL | pravastatin sodium | TABLET;ORAL | 019898-003 | Oct 31, 1991 | AB | RX | Yes | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | BARACLUDE | entecavir | SOLUTION;ORAL | 021798-001 | Mar 29, 2005 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-002 | Sep 29, 1986 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bristol Myers Squibb | ZERIT XR | stavudine | CAPSULE, EXTENDED RELEASE;ORAL | 021453-001 | Dec 31, 2002 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-005 | Oct 9, 1991 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET, TABLET, TABLET;ORAL | 021387-002 | Jun 24, 2003 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
apixaban | Tablets | 2.5 mg and 5 mg | ELIQUIS | 12/28/2016 |
naloxone hydrochloride | Nasal Spray | 4 mg/spray | NARCAN | 7/15/2016 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/17/2011 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/16/2011 |
dasatinib | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | SPRYCEL | 6/28/2010 |
entecavir | Tablets | 0.5 mg and 1 mg | BARACLUDE | 6/14/2010 |
atazanavir sulfate | Capsules | 100 mg and 150 mg | REYATAZ | 3/19/2010 |
atazanavir sulfate | Capsules | 200 mg | REYATAZ | 2/16/2010 |
atazanavir sulfate | Capsules | 300 mg | REYATAZ | 7/20/2009 |
efavirenz | Tablets | 600 mg | SUSTIVA | 4/9/2009 |
pravastatin sodium | Tablets | 30 mg | PRAVACHOL | 6/1/2005 |
didanosine | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | VIDEX EC | 6/1/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,858,616 | Nitrogen containing heterobicycles as factor Xa inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 5,965,729 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent | ► Subscribe | |||||||||||||||||||||||||||
| 7,691,846 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 7,960,411 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 8,993,567 | Cyclic protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bulgaria | 64774 | ► Subscribe | |||||||||||||||||||||||||||
| African Intellectual Property Organization (OAPI) | 11400 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2008519049 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 1140941 | ► Subscribe | |||||||||||||||||||||||||||
| Poland | 190744 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2005 | Austria | ► Subscribe | PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005 | ||||||||||||||||||||||||||
| 2005 00037 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| 2107069/02 | Switzerland | ► Subscribe | PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013 | ||||||||||||||||||||||||||
| 5006-2008 | Slovakia | ► Subscribe | PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408 | ||||||||||||||||||||||||||
| 2014026,C1506211 | Lithuania | ► Subscribe | PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,121 others who get our Drug Patent Expiration Alerts:
